pam tıp derg Pamukkale Medical Journal 1308-0865 Pamukkale Üniversitesi Dermatology Dermatoloji Secukinumab, in vitro psoriasis modelinde uzun kodlamayan RNA’lar (lncRNA) MEG3 ve MSX2P1’in ekspresyon düzeylerini etkilemesi Secukinumab affects the expression levels of LncRNAs MEG3 and MSX2P1 in an in vitro psoriasis model https://orcid.org/0000-0002-2172-1128 Kurtoglu Omer Seyfettin PAMUKKALE UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES, MEDICAL DEPARTMENT OF BIOLOGY https://orcid.org/0000-0001-7483-1147 Açıkbaş İbrahim PAMUKKALE UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES, MEDICAL DEPARTMENT OF BIOLOGY https://orcid.org/0000-0002-5335-3835 Er Urgancı Buket PAMUKKALE UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES, MEDICAL DEPARTMENT OF BIOLOGY https://orcid.org/0009-0007-7234-432X Azizi Zahra PAMUKKALE UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES, MEDICAL DEPARTMENT OF BIOLOGY https://orcid.org/0000-0001-9422-5996 Doğan Cihangir PAMUKKALE UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES, MEDICAL DEPARTMENT OF BIOLOGY 04 13 2026 19 2 363 370 08 17 2025 09 02 2025 Copyright © 2008, Pamukkale Tıp Dergisi 2008 Pamukkale Tıp Dergisi

Amaç: Psoriasis, tekrarlayan ve pullu plaklarla karakterize edilen yaygın bir kronik inflamatuar deri hastalığıdır. IL-17, hastalığın patogenezinde merkezi bir rol oynamakta olup, IL-17A’yı hedefleyen monoklonal bir antikor olan Secukinumab bu amaçla yaygın olarak kullanılmaktadır. Uzun zincirli kodlamayan RNA’lar (lncRNA’lar), keratinosit proliferasyonu ve bağışıklık yanıtlarının düzenlenmesinde rol oynamaktadır; ancak IL-17 blokajına verdikleri yanıt hâlâ net olarak bilinmemektedir. Bu çalışma, bir psoriasis hücre kültürü modelinde IL-17 inhibitörü Secukinumab’ın, keratinosit proliferasyonu ve inhibisyonunda rol oynayan MEG3 ve MSX2P1 adlı iki lncRNA’nın ekspresyonu üzerindeki etkisini araştırmayı amaçlamaktadır.Gereç ve yöntem: HaCaT hücreleri, inflamatuar koşulları taklit etmek amacıyla lipopolisakkarit (LPS) ile uyarılmış ve ardından çeşitli dozlarda Secukinumab ile tedavi edilmiştir. Hücre canlılığı 24, 48 ve 72 saatlerde CCK-8 yöntemi ile değerlendirilmiş ve 7,5 mg/ml konsantrasyonu LD₅₀ olarak belirlenmiştir. RNA izolasyonu yapılmış ve gen ekspresyon seviyeleri qRT-PCR yöntemiyle ölçülmüştür.Bulgular: Secukinumab tedavisi sonrası, kontrol grubuna kıyasla MEG3 ekspresyonunda yaklaşık 20 kat, MSX2P1 ekspresyonunda ise yaklaşık 190 kat azalma gözlenmiştir. Bu bulgular, IL-17 inhibisyonunun, proliferasyon ve inflamasyonla ilişkili lncRNA’ların modülasyonu yoluyla keratinosit fonksiyonunu etkileyebileceğini düşündürmektedir.Sonuç: Secukinumab keratinositlerde önemli lncRNA’ların ekspresyon düzenini değiştirebilmektedir. Psoriasis’in klinik yönetiminde bu değişikliklerin rolünü ve ilişkili moleküler yolları aydınlatmak için ileri çalışmalara ihtiyaç vardır.

Purpose: Psoriasis is a common chronic inflammatory skin disease characterized by recurrent, scaly plaques. IL-17 plays a central role in its pathogenesis, and Secukinumab—an anti-IL-17A monoclonal antibody—is widely used for treatment. Long non-coding RNAs (LncRNAs) regulate keratinocyte proliferation and immune responses, yet their response to IL-17 inhibition remains unclear. This study aimed to investigate the effect of Secukinumab on MEG3 and MSX2P1 lncRNA expression in a psoriasis cell culture model.Materials and methods: HaCaT cells were stimulated with lipopolysaccharide (LPS) to mimic inflammatory conditions, followed by treatment with various doses of secukinumab. Cell viability was assessed at 24, 48, and 72 hours using CCK-8, with 7.5 mg/ml determined as the LD₅₀ concentration. RNA was isolated, and gene expression levels were measured via qRT-PCR.Results: The results demonstrated an approximately 20-fold reduction in MEG3 expression and an approximately 190-fold reduction in MSX2P1 expression following secukinumab treatment compared to the control group. These findings suggest that IL-17 inhibition may influence keratinocyte function through the modulation of LncRNAs associated with proliferation and inflammation.Conclusion: Secukinumab appears to alter the expression patterns of key LncRNAs in keratinocytes. Further investigation is warranted to clarify the downstream molecular pathways involved and their relevance in the clinical management of psoriasis.

 Psoriasis MEG3 MSX2P1 secukinumab long non-coding RNA Psoriasis MEG3 MSX2P1 secukinumab uzun kodlamayan RNA Scientific Research Coordination Unit of Pamukkale University Project No 2021SABE020 2021SABE020 Jiang WW, Wang YM, Wang XY, Zhang Q, Zhu SM, Zhang CL. Role and mechanism of matrine alone and combined with acitretin for HaCaT cells and psoriasis-like murine models. Chin Med J (Engl). 2019;132(17):2079-2088. doi:10.1097/CM9.0000000000000412, Baroni A, Buommino E, De Gregorio V, Ruocco E, Ruocco V, Wolf R. Structure and function of the epidermis related to barrier properties. Clin Dermatol. 2012;30(3):257-262. doi:10.1016/j.clindermatol.2011.08.007 Capon F. The genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526. doi:10.3390/IJMS18122526 Zhou Q, Yu Q, Gong Y. Construction of a lncRNAmiRNAmRNA network to determine the regulatory roles of lncRNAs in psoriasis. doi:10.3892/etm.2019.8035 Yang EJ, Beck KM, Liao W. Secukinumab in the treatment of psoriasis: patient selection and perspectives. Psoriasis (Auckl). 2018;8:75-82. doi:10.2147/PTT.S146004 Catia de Felice C, Marulli GC, Ardigò M, Berardesca E. Biological markers in the etiology of psoriasis: Targeted treatment options. 2007;1(1):11-18. Jia HY, Zhang K, Lu WJ, Xu GW, Zhang JF, Tang ZL. LncRNA MEG3 influences the proliferation and apoptosis of psoriasis epidermal cells by targeting miR-21/caspase-8. BMC Mol Cell Biol. 2019;20(1):1-13. doi:10.1186/S12860-019-0229-9/TABLES/1 Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol. 2012;48(3):R45-R53. doi:10.1530/JME-12-0008 Tang ZL, Zhang K, Lv SC, Xu GW, Zhang JF, Jia HY. LncRNA MEG3 suppresses PI3K/AKT/mTOR signalling pathway to enhance autophagy and inhibit inflammation in TNF-α-treated keratinocytes and psoriatic mice. Cytokine. 2021;148. doi:10.1016/j.cyto.2021.155657 Holland PWH, Booth HAF, Bruford EA. Classification and nomenclature of all human homeobox genes. BMC Biol. 2007;5(1):1-28. doi:10.1186/1741-7007-5-47/TABLES/1 Qiao M, Li R, Zhao X, Yan J, Sun Q. Up-regulated lncRNA-MSX2P1 promotes the growth of IL-22-stimulated keratinocytes by inhibiting miR-6731-5p and activating S100A7. Exp Cell Res. 2018;363(2):243-254. doi:10.1016/J.YEXCR.2018.01.014 Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. The Lancet. 2021;397(10275):754-766. doi:10.1016/S0140-6736(21)00184-7 Atakan N. Secukinumab. Turkderm Turk Arch Dermatol Venereol 2025;56(1):52-54. doi:10.4274/turkderm.galenos.2022.37929 Costache DO, Feroiu O, Ghilencea A, et al. Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis. Int J Mol Sci. 2022;23(9):5198. doi:10.3390/IJMS23095198 Chen Y, Hu Y, Zhou X, et al. Human umbilical cord-derived mesenchymal stem cells ameliorate psoriasis-like dermatitis by suppressing IL-17-producing γδ T cells. Cell Tissue Res. 2022;388(3):549-563. doi:10.1007/S00441-022-03616-X Shi R, Ma R, Jiang X, et al. Implications of LncRNAs and CircRNAs in psoriasis: a review. RNA Biol. 2023;20(1):334-337. doi:10.1080/15476286.2023.2223486 Shi Y, Chen Z, Zhao Z, et al. IL-21 induces an imbalance of Th17/treg cells in moderate-to-severe plaque psoriasis patients. Front Immunol. 2019;10:1865. doi:10.3389/FIMMU.2019.01865